J Korean Med Assoc.  2017 Feb;60(2):183-193. 10.5124/jkma.2017.60.2.183.

Crinical diagnostic guidelines for allergic rhinitis: medical treatment

Affiliations
  • 1Department of Otorhinolaryngology, Inha University College of Medicine, Incheon, Korea.
  • 2Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  • 3Department of Pediatrics, Soonchunhyang University College of Medicine, Seoul, Korea.
  • 4SCH Biomedical Informatics Research Unit, Seoul, Korea.
  • 5Department of Pulmonology and Allergy, Hallym University College of Medicine, Chuncheon, Korea.
  • 6Departments of Otorhinolaryngology-Head and Neck Surgery, Hallym University College of Medicine, Chuncheon, Korea.
  • 7Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.
  • 8Allergy Immunology Center, Korea University, Seoul, Korea.
  • 9Department of Biostatistics, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
  • 10Department of Pediatrics, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
  • 11Wooridul Private Internal Clinic, Gwangju, Korea.
  • 12Department of Pediatrics, Inha University College of Medicine, Incheon, Korea.
  • 13A & A Clinic, Seongnam, Korea.
  • 14Department of Otorhinolaryngology, Head and Neck Surgery, Dong-A University College of Medicine, Busan, Korea.
  • 15Department of Otorhinolaryngology-Head and Neck Surgery, Catholic Kwandong Universtiy College of Medicine, Incheon, Korea.
  • 16Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea.
  • 17Division of Pulmonology and Allergy, Department of Internal Medicine, Gachon University College of Medicine, Incheon, Korea.
  • 18GF Allergy Clinic, Seoul, Korea.
  • 19Lee & Hong ENT, Seongnam, Korea.
  • 20Cho&Park ENT Clinics, Suwon, Korea.
  • 21Department of Pediatrics, CHA University School of Medicine, Seongnam, Korea.
  • 22Department of Pediatrics, Sanbon Hospital, Wonkwang University College of Medicine, Gunpo, Korea. pyallergy@gmail.com
  • 23Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. yikoh@chonnam.ac.kr

Abstract

The social and economic burden of allergic rhinitis (AR) is increasing, with significant effects on the quality of life of patients suffering from AR. Therefore, physicians require evidence-based guidelines regarding the diagnosis, differential diagnosis and proper management management of patients with AR. The Korean Academy of Asthma, Allergy and Clinical Immunology developed new clinical guidelines for the appropriate management of AR, especially in Korean patients. For the core questions (i.e. questions that most practitioners were curious about), several experts in the field of allergology, pediatrics, and otorhinolaryngology developed a set of practical guidelines based on a systematic review of the literature. Furthermore, we determined the level of evidence associated with the recommendations for each answer. In this article, we suggest 15 answers for core questions about the medical treatment of AR.

Keyword

Rhinitis, allergic; Guideline; Medicine; Therapeutics

MeSH Terms

Allergy and Immunology
Asthma
Diagnosis
Diagnosis, Differential
Humans
Hypersensitivity
Otolaryngology
Pediatrics
Quality of Life
Rhinitis, Allergic*

Reference

1. Nurmatov U, van Schayck CP, Hurwitz B, Sheikh A. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy. 2012; 67:158–165.
Article
2. Terreehorst I, Hak E, Oosting AJ, Tempels-Pavlica Z, de Monchy JG, Bruijnzeel-Koomen CA, Aalberse RC, Gerth van Wijk R. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med. 2003; 349:237–246.
Article
3. Custovic A, Murray CS, Gore RB, Woodcock A. Controlling indoor allergens. Ann Allergy Asthma Immunol. 2002; 88:432–441.
Article
4. Kilburn S, Lasserson TJ, McKean M. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev. 2003; (1):CD002989.
Article
5. Bjornsdottir US, Jakobinudottir S, Runarsdottir V, Juliusson S. The effect of reducing levels of cat allergen (Fel d 1) on clinical symptoms in patients with cat allergy. Ann Allergy Asthma Immunol. 2003; 91:189–194.
Article
6. Burr ML, Matthews IP, Arthur RA, Watson HL, Gregory CJ, Dunstan FD, Palmer SR. Effects on patients with asthma of eradicating visible indoor mould: a randomised controlled trial. Thorax. 2007; 62:767–772.
Article
7. Kercsmar CM, Dearborn DG, Schluchter M, Xue L, Kirchner HL, Sobolewski J, Greenberg SJ, Vesper SJ, Allan T. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006; 114:1574–1580.
Article
8. Bernstein JA, Bobbitt RC, Levin L, Floyd R, Crandall MS, Shalwitz RA, Seth A, Glazman M. Health effects of ultraviolet irradiation in asthmatic children's homes. J Asthma. 2006; 43:255–262.
Article
9. Sever ML, Arbes SJ Jr, Gore JC, Santangelo RG, Vaughn B, Mitchell H, Schal C, Zeldin DC. Cockroach allergen reduction by cockroach control alone in low-income urban homes: a randomized control trial. J Allergy Clin Immunol. 2007; 120:849–855.
Article
10. Simons FE, Luciuk GH, Simons KJ. Pharmacokinetics and efficacy of chlorpheniramine in children. J Allergy Clin Immunol. 1982; 69:376–381.
Article
11. Ng KH, Chong D, Wong CK, Ong HT, Lee CY, Lee BW, Shek LP. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics. 2004; 113:e116–e121.
Article
12. de Blic J, Wahn U, Billard E, Alt R, Pujazon MC. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr Allergy Immunol. 2005; 16:267–275.
Article
13. Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008; 1:145–155.
Article
14. Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, Holgate ST, Zuberbier T. Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010; 65:459–466.
15. Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol. 1995; 95(5 Pt 2):1097–1110.
Article
16. Ledford D. Inadequate diagnosis of nonallergic rhinitis: assessing the damage. Allergy Asthma Proc. 2003; 24:155–162.
17. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CC, Schuller D, Spector SL, Tilles SA. Joint Task Force on Practice; American Academy of Allergy.; Asthma § Immunology; American College of Allergy; Asthma and Immunology. Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008; 122:2 Suppl. S1–S84.
Article
18. Banov CH, Lieberman P. Vasomotor Rhinitis Study Groups. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol. 2001; 86:28–35.
Article
19. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004; 351:2203–2217.
Article
20. McNeely W, Wiseman LR. Intranasal azelastine: a review of its efficacy in the management of allergic rhinitis. Drugs. 1998; 56:91–114.
21. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002; 89:479–484.
Article
22. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Ait-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D. World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63:Suppl 86. 8–160.
23. Min YG. Pathophysiology, diagnosis, and treatment of allergic rhinitis. Korean J Otorhinolaryngol-Head Neck Surg. 2013; 56:256–265.
Article
24. Hurst M, Spencer CM. Ebastine: an update of its use in allergic disorders. Drugs. 2000; 59:981–1006.
25. Rah YH. Allergic rhinitis. J Korean Pediatr Soc. 1998; 41:1.
26. Misges R, Koberlein J. New generation antihistamines as monotherapy or in combination. What is the relevance for daily clinical routine for allergic rhinoconjunctivitis. HNO. 2007; 55:457–464.
27. Mandhane SN, Shah JH, Thennati R. Allergic rhinitis: an update on disease, present treatments and future prospects. Int Immunopharmacol. 2011; 11:1646–1662.
Article
28. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004; 116:338–344.
Article
29. Watanasomsiri A, Poachanukoon O, Vichyanond P. Efficacy of montelukast and loratadine as treatment for allergic rhinitis in children. Asian Pac J Allergy Immunol. 2008; 26:89–95.
30. Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol. 2010; 32:669–674.
Article
31. Cobanoglu B, Toskala E, Ural A, Cingi C. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2013; 13:203–208.
Article
32. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schunemann HJ. Global Allergy and Asthma European Network.; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126:466–476.
Article
33. Segundo GR, Gomes FA, Fernandes KP, Alves R, Silva DA, Taketomi EA. Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments. Biologics. 2009; 3:469–474.
Article
34. Meltzer EO. Pharmacotherapeutic strategies for allergic rhini-tis: matching treatment to symptoms, disease progression, and associated conditions. Allergy Asthma Proc. 2013; 34:301–311.
Article
35. Yilmaz O, Altintas D, Rondon C, Cingi C, Oghan F. Effectiveness of montelukast in pediatric patients with allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2013; 77:1922–1924.
Article
36. Uzzaman A, Story R. Chapter 5: Allergic rhinitis. Allergy Asthma Proc. 2012; 33:Suppl 1. S15–S18.
Article
37. Lieberman P, Pattanaik D. Nonallergic rhinitis. Curr Allergy Asthma Rep. 2014; 14:439.
Article
38. Wight RG, Jones AS, Beckingham E, Andersson B, Ek L. A double blind comparison of intranasal budesonide 400 micrograms and 800 micrograms in perennial rhinitis. Clin Otolaryngol Allied Sci. 1992; 17:354–358.
Article
39. Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy. 1995; 25:737–743.
Article
40. Webb DR, Meltzer EO, Finn AF Jr, Rickard KA, Pepsin PJ, Westlund R, Cook CK. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. Ann Allergy Asthma Immunol. 2002; 88:385–390.
Article
41. Bousquet J, Reid J, van Weel C, Baena Cagnani C, Canonica GW, Demoly P, Denburg J, Fokkens WJ, Grouse L, Mullol K, Ohta K, Schermer T, Valovirta E, Zhong N, Zuberbier T. Allergic rhinitis management pocket reference 2008. Allergy. 2008; 63:990–996.
Article
42. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000; 105:E23.
Article
43. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vandewalker ML, Wanderer A, Damaraju CV, Nolop KB, Mesarina-Wicki B. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000; 105:E22.
Article
44. Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002; 23:407–413.
45. Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol. 2005; 115:940–945.
Article
46. Mener DJ, Shargorodsky J, Varadhan R, Lin SY. Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. Int Forum Allergy Rhinol. 2015; 5:95–103.
Article
47. Blaiss MS, Benninger MS, Fromer L, Gross G, Mabry R, Mahr T, Marple B, Stoloff S. Expanding choices in intranasal steroid therapy: summary of a roundtable meeting. Allergy Asthma Proc. 2006; 27:254–264.
Article
48. Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg. 2003; 129:739–750.
Article
49. Soderberg-Warner ML. Nasal septal perforation associated with topical corticosteroid therapy. J Pediatr. 1984; 105:840–841.
Article
50. Nielsen LP, Dahl R. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials. Am J Respir Med. 2003; 2:55–65.
Article
51. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998; 317:1624–1629.
Article
52. Bernstein DI, Levy AL, Hampel FC, Baidoo CA, Cook CK, Philpot EE, Rickard KA. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2004; 34:952–957.
Article
53. Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, Kaiser HB, Vandewalker ML, Bernstein J, Toler WT, Prillaman BA, Dalal AA, Lee LA, Philpot EE. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009; 30:128–138.
Article
54. Fraunfelder FT, Meyer SM. Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids. Am J Ophthalmol. 1990; 109:489–490.
Article
55. Okubo K, Kurono Y, Fujieda S, Ogino S, Uchio E, Odajima H, Takenaka H. Japanese Society of Allergology. Japanese Guideline for Allergic Rhinitis 2014. Allergol Int. 2014; 63:357–375.
Article
56. Brooks CD, Karl KJ, Francom SF. Oral methylprednisolone acetate (Medrol Tablets) for seasonal rhinitis: examination of dose and symptom response. J Clin Pharmacol. 1993; 33:816–822.
Article
57. Martinez-Devesa P, Patiar S. Oral steroids for nasal polyps. Cochrane Database Syst Rev. 2011; (7):CD005232.
Article
58. Mullol J, Alobid I. Combined oral and intranasal corticosteroid therapy: an advance in the management of nasal polyposis. Ann Intern Med. 2011; 154:365–367.
Article
59. Ostergaard MS, Ostrem A, Soderstrom M. Hay fever and a single intramuscular injection of corticosteroid: a systematic review. Prim Care Respir J. 2005; 14:124–130.
Article
60. Felson DT, Anderson JJ. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet. 1987; 1:902–906.
Article
61. Eccles R, Eriksson M, Garreffa S, Chen SC. The nasal decongestant effect of xylometazoline in the common cold. Am J Rhinol. 2008; 22:491–496.
Article
62. Eccles R, Martensson K, Chen SC. Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold. Curr Med Res Opin. 2010; 26:889–899.
Article
63. Taverner D, Latte J. Nasal decongestants for the common cold. Cochrane Database Syst Rev. 2007; (1):CD001953.
Article
64. Ciprandi G, Ricca V, Passalacqua G, Truffelli T, Bertolini C, Fiorino N, Riccio AM, Bagnasco M, Canonica GW. Seasonal rhinitis and azelastine: long- or short-term treatment. J Allergy Clin Immunol. 1997; 99:301–307.
65. Ciprandi G, Passalacqua G, Mincarini M, Ricca V, Canonica GW. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol. 1997; 79:507–511.
Article
66. Canonica GW, Fumagalli F, Guerra L, Baiardini I, Compalati E, Rogkakou A, Massacane P, Gamalero C, Riccio AM, Scor-damaglia A, Passalacqua G. Global Allergy and Asthma European Network. Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. Curr Med Res Opin. 2008; 24:2829–2839.
Article
67. Laekeman G, Simoens S, Buffels J, Gillard M, Robillard T, Benedetti MS, Watelet JB, Liekendael G, Ghys L, Church M. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice. Respir Med. 2010; 104:615–625.
Article
68. Bende M, Carrillo T, Vona I, da Castel-Branco MG, Arheden L. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2002; 88:617–623.
Article
69. Pitsios C, Papadopoulos D, Kompoti E, Manoussakis E, Garris V, Petalas K, Tassios I, Baibas N, Kontou-Fili K, Saxoni-Papageorgiou P, Papadopoulos NG. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006; 96:673–678.
Article
70. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, Dawson DE, Dykewicz MS, Hackell JM, Han JK, Ishman SL, Krouse HJ, Malekzadeh S, Mims JW, Omole FS, Reddy WD, Wallace DV, Walsh SA, Warren BE, Wilson MN, Nnacheta LC. Guideline Otolaryngology Development Group. AAO-HNSF Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015; 152:1 Suppl. S1–S43.
71. Kim SW, Park DJ, Min JY, Park KJ, Won TB, Cho JH. Medical treatment of allergic rhinitis. Korean Rhinologic Society. Guidelines for allergic rhinitis. Seoul: Jungangmunhwasa;2012. p. 46–50.
72. Mucha SM, deTineo M, Naclerio RM, Baroody FM. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2006; 132:164–172.
Article
73. Lee JY, Lee JD. Comparative study on the long-term effectiveness between coblation- and microdebrider-assisted partial turbinoplasty. Laryngoscope. 2006; 116:729–734.
Article
Full Text Links
  • JKMA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr